Tandem Diabetes Care Achieves Milestone of 1 Million Insulin Boluses Delivered Using Its t:connect Mobile App
Tandem Diabetes Care (NASDAQ:TNDM) announced that users of its t:slim X2 insulin pump have delivered over 1 million insulin boluses via the t:connect app within a month of its launch. This app, the first FDA-cleared one for initiating insulin delivery on smartphones, supports both iOS and Android on approximately 30 devices. Users can activate this feature at no additional cost. CEO John Sheridan emphasized the importance of innovative technology for improving diabetes management.
- Over 1 million insulin boluses delivered via t:connect app in first month.
- First FDA-cleared app for smartphone insulin delivery on iOS and Android.
- Feature available at no additional cost to existing t:slim X2 users.
- None.
“The rapid adoption of our mobile bolus feature demonstrates the importance of our offering new technologies that provide lifestyle benefits, in addition to improved clinical outcomes, to people living with diabetes,” said
The t:connect mobile app is designed to offer t:slim X2 insulin pump users the ability to program and cancel bolus insulin requests through the convenience of their compatible smartphone. It is the first-ever FDA-cleared smartphone application capable of initiating insulin delivery on both iOS and Android operating systems and is now available on approximately 30 different devices.
“The ability to bolus from my phone has been a game changer,” said
Current t:slim X2 pump users in
For more information on the process or to get started, visit https://www.tandemdiabetes.com/support/software-updates/how-to-update/mobile-bolus.
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements relate to, among other things, our goal to continually enhance the solutions we provide and offer best-in-class customer care. These forward-looking statements are subject to numerous risks and uncertainties, including risks associated with the research and development process generally, such as the design, testing and validation of products and related systems in compliance with applicable regulatory and legal requirements in the markets that we serve, our ability to develop, scale and maintain systems, personnel and infrastructure to support customers across diverse geographies and market segments, as well as other risks identified in our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and other documents that we file with the
About
Visit www.tandemdiabetes.com/mobile-bolus for important safety information.
Follow
Follow
Follow
View source version on businesswire.com: https://www.businesswire.com/news/home/20220818005190/en/
Media Contact:
714-907-6264
ssabicer@thesabicergroup.com
Investor Contact:
858-366-6900
IR@tandemdiabetes.com
Source:
FAQ
What is the significance of the t:connect app for Tandem Diabetes Care users?
How many insulin boluses have t:slim X2 users delivered using the t:connect app?
What devices support the t:connect app for insulin delivery?
Is there an additional cost for existing t:slim X2 users to access the t:connect app?